Enliven Therapeutics (ELVN) Stock Chart & Stock Price History → Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning (From American Hartford Gold Group) (Ad) Free ELVN Stock Alerts $24.10 -0.39 (-1.59%) (As of 10:27 AM ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Enliven Therapeutics Stock Price Performance5 Day Performance+6.40%1 Month Performance+25.59%3 Month Performance+51.10%6 Month Performance+108.66%Year-To-Date Performance+74.13%1 Year Performance+25.59% Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ELVN Stock Chart for Thursday, May, 9, 2024 ELVN Chart by TradingView Enliven Therapeutics Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/08/2024$24.70$24.49-0.85%$24.60$23.72432,449 shs$1.15 billion05/07/2024$22.92$24.70+7.77%$25.00$22.92608,889 shs$1.16 billion05/06/2024$22.65$22.92+1.19%$22.96$22.20307,122 shs$1.08 billion05/03/2024$20.99$22.65+7.91%$23.00$21.35482,543 shs$1.06 billion05/02/2024$18.10$20.99+15.97%$21.12$18.29221,412 shs$986.74 million05/01/2024$17.39$18.10+4.08%$18.76$17.68176,816 shs$850.88 million Get the Latest News and Ratings for ELVN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 04/30/2024$17.79$17.39-2.25%$18.34$17.35792,794 shs$814.03 million04/29/2024$17.18$17.79+3.55%$18.79$17.41283,528 shs$832.75 million04/26/2024$16.78$17.18+2.38%$17.52$16.16148,934 shs$804.20 million04/25/2024$17.49$16.78-4.06%$17.36$16.53602,668 shs$785.47 million04/24/2024$17.37$17.49+0.69%$17.94$17.15221,584 shs$818.71 million04/23/2024$17.62$17.37-1.42%$18.20$17.01368,498 shs$813.09 million04/22/2024$17.28$17.62+1.97%$17.99$16.87280,702 shs$824.79 million04/19/2024$17.67$17.28-2.21%$18.51$15.96763,125 shs$808.88 million04/18/2024$17.30$17.67+2.14%$18.27$16.76211,501 shs$827.13 million04/17/2024$18.69$17.30-7.44%$19.45$17.09186,911 shs$712.76 million04/16/2024$19.94$18.69-6.27%$20.60$18.59147,810 shs$770.03 million04/15/2024$21.08$19.94-5.41%$21.19$19.55745,161 shs$821.53 million04/12/2024$23.82$21.08-11.50%$24.20$20.00853,372 shs$868.50 million04/11/2024$19.82$23.82+20.18%$26.00$22.623.35 million shs$981.38 million04/10/2024$19.19$19.82+3.28%$21.16$17.99832,208 shs$816.58 million04/09/2024$18.30$19.19+4.86%$19.97$18.27140,495 shs$790.63 million04/08/2024$19.40$18.30-5.67%$19.49$17.7087,392 shs$753.96 million04/05/2024$18.60$19.40+4.30%$19.65$18.17230,632 shs$799.28 million04/04/2024$18.59$18.60+0.05%$19.45$18.50184,850 shs$766.32 million04/03/2024$18.80$18.59-1.12%$19.00$18.04129,028 shs$765.91 million04/02/2024$18.90$18.80-0.53%$19.08$17.35383,056 shs$774.56 million04/01/2024$17.59$18.90+7.45%$19.36$17.32285,762 shs$778.68 million03/29/2024$17.59$17.59$18.69$17.36196,400 shs$724.71 million03/28/2024$18.63$17.59-5.58%$18.69$17.36196,384 shs$724.71 million03/27/2024$17.61$18.63+5.79%$18.81$17.5084,205 shs$767.56 million03/26/2024$17.78$17.61-0.96%$18.41$17.3497,388 shs$725.53 million03/25/2024$18.48$17.78-3.79%$18.89$16.81170,032 shs$732.54 million03/22/2024$18.06$18.48+2.33%$18.99$17.50137,240 shs$764.15 million03/21/2024$19.21$18.06-5.99%$19.20$17.59158,300 shs$746.78 million03/20/2024$17.54$19.21+9.52%$19.50$16.71252,538 shs$794.33 million03/19/2024$12.64$17.54+38.77%$18.15$14.50666,612 shs$725.28 million03/18/2024$11.97$12.64+5.60%$12.98$11.6774,346 shs$520.89 million03/15/2024$11.54$11.97+3.73%$12.26$11.02643,091 shs$493.28 million03/14/2024$12.27$11.54-5.95%$13.11$11.3596,076 shs$475.56 millionThe A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.03/13/2024$12.75$12.27-3.76%$12.83$12.2479,511 shs$505.65 million03/12/2024$13.48$12.75-5.42%$13.59$12.16221,118 shs$525.43 million03/11/2024$14.87$13.48-9.35%$14.69$13.4161,508 shs$555.51 million03/08/2024$15.40$14.87-3.44%$15.87$14.4746,231 shs$612.79 million03/07/2024$15.45$15.40-0.32%$16.11$15.2853,207 shs$634.63 million03/06/2024$16.04$15.45-3.68%$16.43$15.1942,263 shs$636.69 million03/05/2024$16.67$16.04-3.78%$16.41$15.8529,860 shs$661.01 million03/04/2024$16.67$16.67$17.10$15.7248,423 shs$686.97 million03/01/2024$15.97$16.67+4.38%$17.14$15.9655,164 shs$686.97 million02/29/2024$17.00$15.97-6.06%$17.29$15.87133,354 shs$658.12 million02/28/2024$17.68$17.00-3.85%$17.67$17.0068,068 shs$700.57 million02/27/2024$17.56$17.68+0.68%$18.02$16.6065,278 shs$728.59 million02/26/2024$16.53$17.56+6.23%$17.61$16.3178,377 shs$723.65 million02/23/2024$15.90$16.53+3.96%$16.84$15.8239,375 shs$681.20 million02/22/2024$16.16$15.90-1.61%$16.81$15.3366,156 shs$655.24 million02/21/2024$16.57$16.16-2.47%$16.33$15.1954,894 shs$665.95 million02/20/2024$16.79$16.57-1.31%$18.00$15.5935,708 shs$682.85 million02/19/2024$16.79$16.79$17.70$16.6874,800 shs$691.92 million02/16/2024$17.30$16.79-2.95%$17.70$16.6874,876 shs$691.92 million02/15/2024$17.17$17.30+0.76%$17.88$16.96169,686 shs$712.93 million02/14/2024$14.85$17.17+15.62%$17.31$14.89929,915 shs$707.58 million02/13/2024$16.62$14.85-10.65%$16.42$14.7998,798 shs$611.97 million02/12/2024$15.95$16.62+4.20%$16.98$15.2588,863 shs$684.91 million02/09/2024$15.41$15.95+3.50%$16.86$14.2161,960 shs$657.30 million02/08/2024$15.22$15.41+1.25%$16.35$14.6859,463 shs$635.05 million Related Companies: 89bio Stock Chart Tango Therapeutics Stock Chart Arcutis Biotherapeutics Stock Chart Sage Therapeutics Stock Chart Immunome Stock Chart ARS Pharmaceuticals Stock Chart Zentalis Pharmaceuticals Stock Chart OPKO Health Stock Chart ALX Oncology Stock Chart Longboard Pharmaceuticals Stock Chart Receive ELVN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ELVN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.